AbCellera Biologics Inc. (ABCL) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody medicines. The company is transitioning from a primarily partnership-focused model to one that includes significant internal development of its own pipeline, including programs ABCL635, ABCL575, and ABCL688.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $8,315 | $4,235 |
| Net Loss | $(43,165) | $(45,621) |
| Net Loss Per Share (Basic & Diluted) | $(0.14) | $(0.15) |
| Operating Expenses | $65,834 | $66,895 |
| Cash, Cash Equivalents & Marketable Securities | $504,732 | $533,826 |
| Net Cash Used in Operating Activities | $(33,523) | $(11,554) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 96% ($4.1 million) year-over-year, driven primarily by a 100% increase in research fees ($8.1 million vs. $4.1 million).
- Expense Management: Total operating expenses decreased slightly by 1.6% ($1.1 million). This was due to a 35% reduction in Sales, General, and Administrative (SG&A) expenses ($12.3 million vs. $19.1 million), offset by a 10% increase in Research and Development (R&D) expenses ($46.7 million vs. $42.5 million).
- R&D Drivers: The increase in R&D was primarily due to $3.8 million in external clinical costs for ABCL575 and ABCL635, which entered clinical trials in late 2025. Preclinical costs decreased as IND-enabling activities concluded.
- Liquidity: Total cash and marketable securities decreased by $29.1 million to $504.7 million. This reduction was driven by operating cash outflows, partially offset by the collection of $18.0 million from a litigation settlement receivable.
Guidance, Outlook, and Risks
- Clinical Milestones:
- ABCL635: Positive interim Phase 1 data announced in May 2026 showing potent target engagement and a favorable safety profile. Phase 2 topline data is anticipated in Q3 2026.
- ABCL575: Phase 1 topline data is anticipated in Q4 2026.
- ABCL688: IND/CTA submission is anticipated in 2027.
- Liquidity Outlook: Management believes current liquidity ($504.7 million in cash/securities plus government contributions) is sufficient to fund operations and capital expenditures for at least the next 36 months.
- Strategic Shift: The company is pivoting resources toward internal pipeline development, which increases near-term cash costs and exposure to clinical trial risks compared to the historical partnership model.
- Risks:
- Profitability: The company has incurred losses since inception and expects to continue doing so. There is no guarantee of achieving profitability.
- Clinical Uncertainty: Interim data may change; clinical trials may fail or be delayed. Regulatory approval is not guaranteed.
- Partnership Dependency: Future revenue relies heavily on partners successfully developing and commercializing antibodies discovered by AbCellera.
- Legal Proceedings: Ongoing litigation with the Estate of John Schrader regarding patent infringement and partnership claims.
Investor Verification Checklist
- Verify the timing and results of the ABCL635 Phase 2 topline data readout expected in Q3 2026.
- Monitor the collection of the remaining $18.0 million from the litigation settlement receivable.
- Review the status of the Schrader litigation and potential financial impact.
- Assess the burn rate relative to the 36-month liquidity runway, specifically regarding the transition to internal clinical development.
- Confirm the progress of ABCL575 Phase 1 and ABCL688 IND-enabling studies.